Edition:
United Kingdom

XBiotech Inc (XBIT.OQ)

XBIT.OQ on NASDAQ Stock Exchange Global Select Market

2.79USD
19 Sep 2018
Change (% chg)

$-0.09 (-3.12%)
Prev Close
$2.88
Open
$2.86
Day's High
$2.86
Day's Low
$2.79
Volume
1,568
Avg. Vol
37,048
52-wk High
$5.80
52-wk Low
$2.13

Chart for

About

XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): $157.97
Shares Outstanding(Mil.): 35.42
Dividend: --
Yield (%): --

Financials

  XBIT.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -1.47 -- --
ROI: -62.28 1.78 14.61
ROE: -62.30 3.29 16.33

BRIEF-XBiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology

* XBIOTECH ANNOUNCES UPCOMING PHASE 2 CLINICAL STUDIES IN DERMATOLOGY

16 Apr 2018

BRIEF-Xbiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology

* XBIOTECH ANNOUNCES UPCOMING PHASE 2 CLINICAL STUDIES IN DERMATOLOGY

16 Apr 2018

BRIEF-XBiotech In-Licenses Anti-NY-ESO 1 Antibody Targeting Advanced Cancer

* HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG Source text for Eikon: Further company coverage:

02 Apr 2018

Earnings vs. Estimates